Article
Oncology
Xiaomao Shi, Jin Peng, Huangang Jiang, Yu Gao, Wenbo Wang, Fuxiang Zhou
Summary: The study found that adjuvant CRT may improve the overall survival of postoperative pancreatic cancer patients compared to adjuvant CT. Survival benefit was more significant in female patients, T3 stage patients, and lymph nodes positive patients.
FRONTIERS IN ONCOLOGY
(2021)
Review
Surgery
Mark Donnelly, Odhran K. Ryan, Eanna J. Ryan, Ben Creavin, Mary O'Reilly, Ray McDermott, Rory Kennelly, Ann Hanly, Sean T. Martin, Des C. Winter
Summary: This study demonstrates that total neoadjuvant therapy (TNT) improves survival and recurrence benefits compared with current standards of care. TNT treatment strategies also improve radiological and oncological responses to treatment, and may increase the number of patients suitable for organ preservation, without negatively influencing treatment toxicity or compliance.
BRITISH JOURNAL OF SURGERY
(2023)
Article
Genetics & Heredity
Agata Stodolna, Miao He, Mahesh Vasipalli, Zoya Kingsbury, Jennifer Becq, Joanne D. Stockton, Mark P. Dilworth, Jonathan James, Toju Sillo, Daniel Blakeway, Stephen T. Ward, Tariq Ismail, Mark T. Ross, Andrew D. Beggs
Summary: Clinical whole-genome sequencing has the potential to identify private genomic variations that may confer sensitivity to targeted therapies, offering patients new options for treatment.
Article
Oncology
Hagen F. Kennecke, Rebecca Auer, May Cho, N. Arvind Dasari, Cynthia Davies-Venn, Cathy Eng, Jennifer Dorth, Julio Garcia-Aguilar, Manju George, Karyn A. Goodman, Lillian Kreppel, Joshua E. Meyer, Jose Monzon, Leonard Saltz, Deborah Schrag, J. Joshua Smith, Jason A. Zell, Prajnan Das, Natl Canc Inst Rectal Anal Task Force
Summary: The optimal management of locally advanced rectal cancer is rapidly evolving. A task force convened by the National Cancer Institute developed consensus on the design of future clinical trials for rectal cancer based on iterative reviews and a Delphi analytical approach. The task force achieved consensus on various aspects, including the use of neoadjuvant therapy, the importance of patient involvement, the identification of patients likely to benefit from nonoperative management or minimally invasive surgery, the utility of circulating tumor DNA measurements, and the need for appropriate end points and data management.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Editorial Material
Medicine, General & Internal
David H. Ilson
Summary: Esophageal cancer is a major cause of cancer-related illness and death worldwide, often presenting with locally advanced or metastatic disease due to lack of effective screening or early detection. Esophageal squamous-cell carcinoma is the most common histologic type globally, especially in high-incidence areas like East Asia, while adenocarcinoma dominates in the West. Surgical outcomes for esophageal squamous-cell cancer patients in 1980 highlighted the significant challenge in treating esophageal cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Jacob L. van Dam, Quisette P. Janssen, Marc G. Besselink, Marjolein Y. Homs, Hjalmar C. van Santvoort, Geertjan van Tienhoven, Roeland F. de Wilde, Johanna W. Wilmink, Casper H. J. van Eijck, Bas Groot Koerkamp
Summary: This study found that neoadjuvant therapy can improve overall survival in patients with borderline resectable pancreatic cancer. However, more evidence is needed to determine whether it also improves survival in patients with resectable pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2022)
Review
Oncology
Yan Yuan, Jiuzhou Chen, Miao Fang, Yaru Guo, Xueqing Sun, Dehong Yu, Yilong Guo, Yong Xin
Summary: Nimotuzumab in combination with chemoradiotherapy has shown better clinical efficacy compared to chemoradiotherapy alone in the treatment of cervical cancer, without increasing toxicity. However, further evidence from large-scale randomized controlled trials is needed.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Bing Li, Fengbin Zhang, Qikai Niu, Jun Liu, Yanan Yu, Pengqian Wang, Siqi Zhang, Huamin Zhang, Zhong Wang
Summary: A refined molecular classification scheme for gastric cancer (GC) was proposed, which utilized integrated optimal algorithms and multi-omics data to guide personalized therapies. Three subtypes linked to distinct clinical outcomes were identified based on selected important features from mRNA, microRNA, and DNA methylation data. These subtypes were validated in multiple independent cohorts and showed better clinical prediction performance compared to The Cancer Genome Atlas classification.
MOLECULAR THERAPY-NUCLEIC ACIDS
(2023)
Editorial Material
Medicine, General & Internal
Hanna K. Sanoff
Summary: The cure rate for nonmetastatic rectal cancer has been improving over the years, with surgery, radiation therapy, and chemotherapy being the routine treatment. Recent studies have shown that adding multiagent chemotherapy to radiation therapy before proctectomy can significantly increase the 3-year disease-free survival rate. However, this treatment approach also comes with severe long-term sequelae.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Joana Vidal, David Casadevall, Beatriz Bellosillo, Carles Pericay, Rocio Garcia-Carbonero, Ferran Losa, Laia Layos, Vicente Alonso, Jaume Capdevila, Javier Gallego, Ruth Vera, Antonieta Salud, Marta Martin-Richard, Miguel Nogue, Elena Cillan, Joan Maurel, Iris Faull, Victoria Raymond, Carlos Fernandez-Martos, Clara Montagut
Summary: The study showed that in patients with LARC undergoing TNT, the detection of presurgery ctDNA identified individuals at high risk of systemic recurrence, with shorter disease-free survival and overall survival. This sets the foundation for future clinical trials using liquid biopsy to personalize treatment post TNT.
CLINICAL CANCER RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Chang In Moon, John Michael Elizarraras, Jonathan Thomas Lei, Byron Jia, Bing Zhang
Summary: This study presents a web application called ClinicalOmicsDB, which allows for exploration of molecular associations of oncology drug responses in clinical trials. The database includes transcriptomic data from 40 clinical trial studies, covering 5913 patients with 11 cancer types. Users can explore the molecular associations of oncology drug responses through three options: studies, treatments or genes.
NUCLEIC ACIDS RESEARCH
(2023)
Review
Oncology
David E. Gerber, Harpreet Singh, Erin Larkins, Andrea Ferris, Patrick M. Forde, Wendy Selig, Upal Basu Roy
Summary: Clinical trial eligibility criteria play a crucial role in controlling patient characteristics, ensuring participant safety, and optimizing result interpretation. However, complex and overly restrictive criteria have posed barriers to patient access, recruitment, and the generalizability of trial results. In response, a working group developed a framework for lung cancer clinical trial eligibility criteria, aiming to simplify criteria, facilitate stakeholder search for trials, and harmonize trial populations for treatment effect comparisons.
Article
Radiology, Nuclear Medicine & Medical Imaging
Xiaofeng Jiang, Hengyu Zhao, Oliver Lester Saldanha, Sven Nebelung, Christiane Kuhl, Iakovos Amygdalos, Sven Arke Lang, Xiaojian Wu, Xiaochun Meng, Daniel Truhn, Jakob Nikolas Kather, Jia Ke
Summary: A deep learning model based on preoperative MRI scans was developed and validated to predict survival in patients with rectal cancer.
Article
Medicine, General & Internal
Jun Lu, Bin-bin Xu, Li-li Shen, Dong Wu, Zhen Xue, Hua-Long Zheng, Jian-Wei Xie, Jia-Bin Wang, Jian-Xian Lin, Qi-Yue Chen, Long-Long Cao, Mi Lin, Ru-Hong Tu, Ze-Ning Huang, Ju-Li Lin, Chang-Ming Huang, Chao-Hui Zheng, Ping Li
Summary: This study described the characteristics of GC RCTs in the past 20 years, identified a burden of research waste, and may provide evidence for the development of rational RCTs and reduction of waste in the future.
Review
Virology
Weijian Lin, Yongxiang Zhao, Liping Zhong
Summary: This review discusses the potential of viruses as a novel immune-active agent for cancer treatment and their use in clinical trials, as well as the challenges and future prospects of virotherapy in the management of cancer patients.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Meeting Abstract
Oncology
Debashis Sarker, Udai Banerji, Sarah Patricia Blagden, Natalie Cook, T. R. Jeffry Evans, Elizabeth Ruth Plummer, Marina Braun, Ann Cleverly, Nieves Diaz, Paul Jones, Ivan Matthews, Sophie Glatt
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Shruthy Suresh, Roy Rabbie, Manik Garg, Dianne Lumaquin, Ting -Hsiang Huang, Emily Montal, Yilun Ma, Nelly M. Cruz, Xinran Tang, Jeremie Nsengimana, Julia Newton-Bishop, Miranda V. Hunter, Yuxin Zhu, Kevin Chen, Elisa de Stanchina, David J. Adams, Richard M. White
Summary: In melanoma, identifying predictive gene signatures in localized tumors that will ultimately metastasize is important for treatment decisions. In this study, data from the AVAST-M trial was used to identify a gene signature that predicts metastasis. GRAMD1B, a cholesterol transfer protein, was found to be a metastasis suppressor. Mechanistically, excess free cholesterol or its metabolite 27-hydroxycholesterol promotes invasiveness through activation of an AP-1 program. Early targeting of these programs can prevent metastatic relapse.
Article
Oncology
David J. Propper, Fangfei Gao, Mark P. Saunders, Debashis Sarker, John A. Hartley, Victoria J. Spanswick, Helen L. Lowe, Louise D. Hackett, Tony T. Ng, Paul R. Barber, Gregory E. Weitsman, Sarah Pearce, Laura White, Andre Lopes, Sharon Forsyth, Daniel Hochhauser
Summary: This study examined the toxicity and efficacy of high-dose pulsed AZD8931 combined with chemotherapy in metastatic colorectal cancer. Results showed acceptable toxicity and some patients had good response to the treatment. Furthermore, a reduction in circulating HER2/3 dimer was observed after treatment.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Robert Jones, Ruth Plummer, Victor Moreno, Louise Carter, Desamparados Roda, Elena Garralda, Rebecca Kristeleit, Debashis Sarker, Tobias Arkenau, Patricia Roxburgh, Harriet S. Walter, Sarah Blagden, Alan Anthoney, Barbara J. Klencke, Mark M. Kowalski, Udai Banerji
Summary: The purpose of this study was to assess the safety, recommended dose, pharmacokinetic profile, and clinical activity of the novel checkpoint kinase 1 (Chk1) inhibitor SRA737 in combination with gemcitabine in patients with advanced solid tumors. The results showed that the combination of SRA737 and low-dose gemcitabine was well tolerated and demonstrated tumor responses in anogenital cancer and other solid tumors.
CLINICAL CANCER RESEARCH
(2023)
Article
Medicine, General & Internal
Cienne Morton, Debashis Sarker, Paul Ross
Summary: Cancers contain numerous mutations, but only a few are critical for malignancy. Targeted therapies and immunotherapy have shown great success in various cancer types. Next-generation sequencing enables the detection of potentially actionable mutations and contributes to the identification of new biomarkers. However, technical challenges and the development of targeted therapies against common genomic aberrations need to be overcome for personalized medicine to become more widely available.
Article
Medicine, General & Internal
Lipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, Juan W. Valle, Chigusa Morizane, Thomas B. Karasic, Thomas A. Abrams, Junji Furuse, Robin K. Kelley, Philippe A. Cassier, Heinz-Josef Kluempen, Heung-Moon Chang, Li-Tzong Chen, Josep Tabernero, Do-Youn Oh, Amit Mahipal, Markus Moehler, Edith P. Mitchell, Yoshito Komatsu, Kunihiro Masuda, Daniel Ahn, Robert S. Epstein, Abdel-Baset Halim, Yao Fu, Tehseen Salimi, Volker Wacheck, Yaohua He, Mei Liu, Karim A. Benhadji, John A. Bridgewater
Summary: In this study, 103 patients with FGFR2-altered intrahepatic cholangiocarcinoma were treated with futibatinib for a median duration of 17.1 months. The results showed that futibatinib treatment could effectively inhibit tumor growth, improve survival, and maintain quality of life for patients.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Cienne Morton, Richard Sullivan, Debashis Sarker, John Posner, James Spicer
Summary: The COVID-19 pandemic has posed a significant threat to cancer patients, impacting their standard care and disrupting clinical trials. However, it has also provided an opportunity for positive reforms in clinical cancer research, as the lessons learned from streamlining processes during the pandemic can be applied to improve the traditionally complex approval, trial design, procedures, and data collection in cancer research.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Rebecca Kristeleit, Ruth Plummer, Robert Jones, Louise Carter, Sarah Blagden, Debashis Sarker, Tobias Arkenau, Thomas R. Jeffry Evans, Sarah Danson, Stefan N. Symeonides, Gareth J. Veal, Barbara J. Klencke, Mark M. Kowalski, Udai Banerji
Summary: This study evaluated the novel Chk1 inhibitor SRA737 in patients with advanced solid tumors. The results showed that SRA737 was well tolerated, but single agent activity did not warrant further development. Therefore, further clinical development of SRA737 should be considered in combination with other drugs.
BRITISH JOURNAL OF CANCER
(2023)
Article
Medicine, General & Internal
Mairead G. McNamara, Jayne Swain, Zoe Craig, Rohini Sharma, Olusola Faluyi, Jonathan Wadsley, Carys Morgan, Lucy R. Wall, Ian Chau, Nick Reed, Debashis Sarker, Jane Margetts, Daniel Krell, Judith Cave, Sharmila Sothi, Alan Anthoney, Christopher Bell, Alkesh Patel, Jamie B. Oughton, David A. Cairns, Wasat Mansoor, Angela Lamarca, Richard A. Hubner, Juan W. Valle
Summary: This study compared the efficacy of liposomal irinotecan/5-FU/folinic acid and docetaxel in the treatment of PD-EP-NEC as second-line therapy. The results showed that liposomal irinotecan/5-FU/folinic acid achieved a 6-month progression-free survival rate of 29.6%, while docetaxel did not meet the primary endpoint. Liposomal irinotecan/5-FU/folinic acid demonstrated manageable toxicity and maintained quality of life.
Article
Oncology
C. Schneider, D. Bogatu, J. Leahy, Y. Zen, P. Ross, D. Sarker, A. Suddle, K. Agarwal, P. Srinivasan, A. A. Prachalias, N. Heaton, K. Menon
Summary: This study compared the outcomes of open resection and laparoscopic resection for hepatocellular carcinoma. The results showed that laparoscopic resection was associated with shorter hospital stay and fewer complications. The long-term outcomes were comparable between the two procedures. The study also identified several predictors for disease-free survival, which can help identify high-risk recurrence patients.
SURGICAL ONCOLOGY-OXFORD
(2023)
Article
Multidisciplinary Sciences
Remi Samain, Oscar Maiques, Joanne Monger, Hoyin Lam, Juliana Candido, Samantha George, Nicola Ferrari, Leonie Kohihammer, Sophia Lunetto, Adrian Varela, Jose L. Orgaz, Felip Vilardell, Jorge Juan Olsina, Xavier Matias-Guiu, Debashis Sarker, Adrian Biddle, Frances R. Balkwill, Jim Eyles, Robert W. Wilkinson, Hemant M. Kocher, Fernando Calvo, Claire M. Wells, Victoria Sanz-Moreno
Summary: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis due to its high metastasis tendency and immunosuppressive microenvironment. The ROCK-Myosin II activity in PDAC cells supports an amoeboid invasive and immunosuppressive program, leading to in vivo metastasis. CD73, an immune checkpoint, is highly expressed in amoeboid PDAC cells and contributes to their invasive, metastatic, and immunomodulatory traits.
Meeting Abstract
Oncology
Ruth Plummer, Mikael Sodergren, Brid Ryan, Ilian Tchakov, Nina Raulf, Rose Hodgson, C. P. Tan, Joanna P. Nicholls, Alison Adderkin, N. Vasileiadou, Vikash Reebye, Tim Meyer, David J. Pinato, Debashis Sarker, Bristi Basu, Sarah Blagden, Natalie Cook, Jeff Evans, Jeffrey Yachnin, Cheng Ean Chee, Dan Li, Anthony El-Khoueiry, Maria Diab, Kai-Wen Huang, Marcus S. Noel, Bridget Keenan, Devalingam Mahalingam, Melanie Grosso, Denis Arnaud, Aurelie Auguste, Jan Storkholm, Iain McNeish, Robert Habib, John J. Rossi, Nagy Habib
Meeting Abstract
Oncology
Debashis Sarker, Sarah Blagden, Natalie Cook, Thomas R. Evans, Ruth Plummer, Angelos Angelakas, Saira Bashir, Salma El Badri, Leonidas Mavroeidis, Cienne Morton, Abdul (Moe) Muhith, Mark White, Rupert Dixon, Elodie Garric, Joanne Mann, Ivan Matthews, Udai Banerji
Meeting Abstract
Oncology
Zoe Craig, Jayne Swain, Rohini Sharma, Olusola Olusesan Faluyi, Jonathan Wadsley, Carys Morgan, Lucy R. Wall, Ian Chau, Nicholas Simon Reed, Debashis Sarker, Jane Margetts, Daniel Krell, Judith Cave, Sothi Sharmila, Alan Anthoney, Alkesh Patel, Angela Lamarca, Richard A. Hubner, Juan W. Valle, Mairead Geraldine McNamara
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Cienne Morton, Daniel Ruta, Chara Stavraka, Kaiser Anam, James F. Spicer, Aoife Regan, Siru Sengul, George Cernile, Yulia Borecki, Taralyn Schwering, Harpreet Rai, Phil Brierley, Oenone Duroe, Alan Quarterman, Debashis Sarker
JOURNAL OF CLINICAL ONCOLOGY
(2022)